Biogen's potentially game-changing Alzheimer's drug still faces an uphill battle with the FDA

Malaysia News News

Biogen's potentially game-changing Alzheimer's drug still faces an uphill battle with the FDA
Malaysia Latest News,Malaysia Headlines
  • 📰 CNBC
  • ⏱ Reading Time:
  • 38 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 72%

'It's a complete coin flip that will now be in the hands of the FDA,' says Jared Holz, a health-care strategist at Jefferies.

The Cambridge, Massachusetts-based company still faces an uphill battle with the federal regulator, however.

"It's a complete coin flip that will now be in the hands of the FDA," said Jared Holz, a health-care strategist at Jefferies, who put the chances of regulatory approval at 60%.The FDA will be under immense pressure from advocacy groups, patients and families living with the disease to approve the drug when Biogen submits it to regulators, likely in early 2020.

Aducanumab targets a "sticky" compound in the brain known as beta-amyloid, which is hypothesized to play a role in the devastating disease. More research is needed on the compound, and not all scientists are convinced that beta-amyloid is the primary cause of Alzheimer's. Many clinical trials targeting the compound have ended in failure.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

CNBC /  🏆 12. in US

Malaysia Latest News, Malaysia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Biogen Details Case for Controversial Alzheimer’s DrugBiogen Details Case for Controversial Alzheimer’s DrugBiogen tried to make the case for why two aborted studies of its experimental Alzheimer’s disease drug support its plan to seek approval from U.S. regulators, but skeptics said they remained unconvinced that the drug is effective.
Read more »

Patients, companies cheer as FDA speedily green-lights drugs. Others are alarmedPatients, companies cheer as FDA speedily green-lights drugs. Others are alarmedThe U.S. is approving new drugs so fast that companies are preparing for a green light months ahead of the scheduled decision date.
Read more »

Biogen Details Case for Controversial Alzheimer’s DrugBiogen Details Case for Controversial Alzheimer’s DrugBiogen tried to make the case for why two aborted studies of its experimental Alzheimer’s disease drug support its plan to seek approval from U.S. regulators, but skeptics said they remained unconvinced that the drug is effective.
Read more »

https://time.comhttps://time.comBreaking news and analysis from TIME.com. Politics, world news, photos, video, tech reviews, health, science and entertainment news.
Read more »

R. Kelly Accused of Bribing Official Day Before Marrying AaliyahR. Kelly Accused of Bribing Official Day Before Marrying AaliyahR. Kelly faces new charges for bribery potentially involving his illegal marriage to Aaliyah
Read more »

New details emerge on drug that may slow Alzheimer’s diseaseNew details emerge on drug that may slow Alzheimer’s diseaseExcitement and skepticism have surrounded the drug since its developers stopped studies earlier this year because it didn't seem to be working.
Read more »



Render Time: 2025-03-13 10:53:08